Profile data is unavailable for this security.
About the company
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
- Revenue in USD (TTM)20.87bn
- Net income in USD1.50bn
- Incorporated1906
- Employees74.00k
- LocationBecton Dickinson and CoOne Becton DriveFRANKLIN LAKES 07417-1880United StatesUSA
- Phone+1 (201) 847-6800
- Websitehttps://www.bd.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agilent Technologies Inc | 6.63bn | 1.17bn | 33.52bn | 18.00k | 29.04 | 5.46 | 23.23 | 5.06 | 4.06 | 4.06 | 23.09 | 21.61 | 0.576 | 3.08 | 5.07 | 370,279.30 | 10.13 | 10.93 | 12.25 | 13.09 | 53.77 | 53.35 | 17.59 | 17.93 | 1.60 | 24.95 | 0.3629 | 21.83 | -4.73 | 4.75 | 3.95 | 3.77 | 19.36 | 7.80 |
| GE HealthCare Technologies Inc | 19.80bn | 2.18bn | 33.92bn | 53.00k | 15.57 | 3.69 | 12.03 | 1.71 | 4.76 | 4.76 | 43.13 | 20.07 | 0.6018 | 5.54 | 4.51 | 373,547.20 | 6.84 | -- | 9.67 | -- | 41.99 | 40.35 | 11.37 | 10.78 | 0.7601 | 8.18 | 0.483 | 1.19 | 0.6138 | 3.41 | 43.48 | 3.82 | 3.91 | -- |
| DexCom Inc | 4.15bn | 535.20m | 34.23bn | 10.30k | 66.94 | 15.10 | 45.01 | 8.25 | 1.30 | 1.30 | 10.11 | 5.78 | 0.6269 | 2.89 | 3.89 | 402,718.40 | 8.09 | 8.79 | 12.44 | 11.75 | 60.72 | 64.97 | 12.90 | 14.90 | 1.32 | -- | 0.5246 | 0.00 | 11.34 | 22.27 | 6.41 | 41.63 | 14.79 | -- |
| Resmed Inc | 5.02bn | 1.31bn | 37.83bn | 9.98k | 28.97 | 6.82 | 24.87 | 7.53 | 8.91 | 8.91 | 34.05 | 37.83 | 0.6983 | 2.45 | 5.65 | 503,159.20 | 18.26 | 14.24 | 20.73 | 16.53 | 58.76 | 56.85 | 26.15 | 20.35 | 2.49 | 58.86 | 0.1082 | 32.62 | 10.95 | 12.44 | 13.75 | 19.98 | 8.23 | 5.89 |
| IDEXX Laboratories Inc | 3.93bn | 894.97m | 43.13bn | 11.00k | 49.56 | 29.91 | 41.92 | 10.97 | 10.82 | 10.82 | 47.53 | 17.93 | 1.20 | 3.87 | 6.81 | 357,439.60 | 27.26 | 28.11 | 40.01 | 42.15 | 61.28 | 59.56 | 22.76 | 22.19 | 0.8111 | 53.37 | 0.3937 | 0.00 | 6.46 | 10.12 | 5.07 | 15.73 | -3.35 | -- |
| Edwards Lifesciences Corp | 5.54bn | 1.44bn | 45.88bn | 15.80k | 32.27 | 4.53 | 29.07 | 8.28 | 2.42 | 7.00 | 9.31 | 17.28 | 0.4867 | 0.984 | 7.45 | 350,557.00 | 12.63 | 14.52 | 14.28 | 16.61 | 79.38 | 79.01 | 25.95 | 25.54 | 3.66 | -- | 0.0554 | 0.00 | 8.57 | 4.58 | 14.55 | 5.94 | 0.2857 | -- |
| Veeva Systems Inc | 2.86bn | 780.66m | 47.06bn | 7.29k | 61.09 | 7.56 | 57.29 | 16.48 | 4.71 | 4.71 | 17.25 | 38.11 | 0.4093 | -- | 6.06 | 391,622.10 | 11.19 | 11.33 | 13.85 | 14.35 | 75.50 | 72.60 | 27.34 | 23.96 | -- | -- | 0.00 | 0.00 | 16.20 | 19.99 | 35.84 | 18.85 | 36.56 | -- |
| Becton Dickinson and Co | 20.87bn | 1.50bn | 49.37bn | 74.00k | 33.36 | 1.96 | 12.77 | 2.37 | 5.16 | 5.16 | 71.96 | 88.07 | 0.3842 | 3.32 | 7.47 | 281,986.50 | 2.76 | 2.55 | 3.20 | 2.92 | 44.68 | 45.30 | 7.18 | 7.29 | 0.6427 | 7.18 | 0.4329 | 76.93 | 4.16 | 3.14 | 15.99 | 10.56 | -5.40 | 4.29 |
| Cencora Inc | 310.23bn | 1.69bn | 58.12bn | 42.00k | 34.80 | 57.37 | 20.67 | 0.1873 | 8.62 | 8.62 | 1,574.00 | 5.23 | 4.59 | 16.40 | 12.70 | 7,386,481.00 | 2.53 | 1.12 | 10.78 | 4.84 | 3.29 | 3.24 | 0.55 | 0.2556 | 0.517 | 17.30 | 0.8694 | 62.15 | 12.12 | 10.36 | -13.53 | 13.02 | 9.45 | 4.98 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 26.66m | 9.29% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 14.79m | 5.15% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 13.99m | 4.87% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2025 | 12.58m | 4.38% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Mar 2025 | 10.89m | 3.79% |
| Geode Capital Management LLCas of 31 Mar 2025 | 6.48m | 2.26% |
| First Eagle Investment Management LLCas of 31 Mar 2025 | 5.52m | 1.92% |
| Generation Investment Management LLPas of 31 Mar 2025 | 5.30m | 1.85% |
| Morgan Stanley Investment Management Ltd.as of 31 Mar 2025 | 4.96m | 1.73% |
| Massachusetts Financial Services Co.as of 31 Mar 2025 | 3.56m | 1.24% |
